Urogen Pharma (NASDAQ:URGN) Receives $32.00 Average Price Target from Analysts

Shares of Urogen Pharma (NASDAQ:URGN) have been given a consensus recommendation of “Buy” by the nine analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $32.00.

URGN has been the topic of a number of analyst reports. Wall Street Zen upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday. Oppenheimer set a $31.00 target price on Urogen Pharma and gave the stock a “buy” rating in a research report on Friday, June 13th. HC Wainwright decreased their target price on Urogen Pharma from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Scotiabank reiterated an “outperform” rating on shares of Urogen Pharma in a research report on Friday, June 13th. Finally, Guggenheim reiterated a “buy” rating and set a $30.00 target price (up from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the business’s stock in a transaction on Monday, August 11th. The stock was sold at an average price of $17.69, for a total transaction of $176,900.00. Following the sale, the insider directly owned 148,229 shares in the company, valued at approximately $2,622,171.01. The trade was a 6.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Jason Drew Smith sold 1,520 shares of the business’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $19.11, for a total value of $29,047.20. Following the sale, the general counsel owned 43,305 shares in the company, valued at approximately $827,558.55. The trade was a 3.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 25,062 shares of company stock worth $465,115. 4.70% of the stock is owned by company insiders.

Institutional Trading of Urogen Pharma

Several institutional investors and hedge funds have recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Urogen Pharma by 216.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company’s stock valued at $48,227,000 after acquiring an additional 2,983,368 shares in the last quarter. RTW Investments LP lifted its position in shares of Urogen Pharma by 1.3% in the fourth quarter. RTW Investments LP now owns 3,834,794 shares of the company’s stock valued at $40,841,000 after acquiring an additional 47,447 shares in the last quarter. RA Capital Management L.P. purchased a new stake in shares of Urogen Pharma in the first quarter valued at $35,461,000. Soleus Capital Management L.P. purchased a new stake in shares of Urogen Pharma in the second quarter valued at $29,934,000. Finally, Vestal Point Capital LP lifted its position in shares of Urogen Pharma by 32.1% in the first quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company’s stock valued at $23,812,000 after acquiring an additional 522,957 shares in the last quarter. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Urogen Pharma Price Performance

Urogen Pharma stock opened at $18.79 on Friday. Urogen Pharma has a 1-year low of $3.42 and a 1-year high of $21.71. The company has a market cap of $869.23 million, a PE ratio of -5.66 and a beta of 1.10. The stock’s 50 day moving average price is $18.19 and its 200 day moving average price is $12.88.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.23). Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. The business had revenue of $24.22 million during the quarter, compared to analysts’ expectations of $23.06 million. On average, equities research analysts anticipate that Urogen Pharma will post -3.12 EPS for the current fiscal year.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.